Telomir Pharmaceuticals (TELO) Interest & Investment Income (2024 - 2026)
Telomir Pharmaceuticals (TELO) posted Interest & Investment Income of $72100.0 for Q4 2025, up 63.19% sequentially from $44182.0 in Q3 2025, and up 921.1% YoY from $7061.0 in Q4 2024.
Telomir Pharmaceuticals (TELO) Interest & Investment Income (2024 - 2026) Analysis & Trends
Telomir Pharmaceuticals has reported Interest & Investment Income for 2 years, with the latest figure at $72100.0 in Q4 2025.
- Quarterly Interest & Investment Income rose 921.1% year-over-year to $72100.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $124705.0 (changed N/A YoY) and the FY2025 annual result came in at $125644.0, up 161.76% from the prior year.
- Interest & Investment Income rose to $72100.0 in Q4 2025 per TELO's latest filing, from $44182.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $72100.0 in Q4 2025 and troughed at $1362.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Telomir Pharmaceuticals | 69.05 Mn | 69.05 Mn | - | 46,176.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46,176.00 |
| Dec 31, 2025 | 72,100.00 |
| Sep 30, 2025 | 44,182.00 |
| Jun 30, 2025 | 1,362.00 |
| Dec 31, 2024 | 7,061.00 |
| Sep 30, 2024 | 15,445.00 |
| Jun 30, 2024 | 25,493.00 |